SG10201910821XA - 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells - Google Patents

1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells

Info

Publication number
SG10201910821XA
SG10201910821XA SG10201910821XA SG10201910821XA SG10201910821XA SG 10201910821X A SG10201910821X A SG 10201910821XA SG 10201910821X A SG10201910821X A SG 10201910821XA SG 10201910821X A SG10201910821X A SG 10201910821XA SG 10201910821X A SG10201910821X A SG 10201910821XA
Authority
SG
Singapore
Prior art keywords
pyrrole
renewal
stem
methods
supporting cells
Prior art date
Application number
SG10201910821XA
Inventor
Christopher Loose
Bradley Tait
Rajesh Manchanda
Will Mclean
Original Assignee
Frequency Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frequency Therapeutics Inc filed Critical Frequency Therapeutics Inc
Publication of SG10201910821XA publication Critical patent/SG10201910821XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201910821XA 2016-12-30 2017-12-21 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells SG10201910821XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662441060P 2016-12-30 2016-12-30
US201762484282P 2017-04-11 2017-04-11

Publications (1)

Publication Number Publication Date
SG10201910821XA true SG10201910821XA (en) 2020-01-30

Family

ID=60972503

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201910821XA SG10201910821XA (en) 2016-12-30 2017-12-21 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells

Country Status (12)

Country Link
US (2) US11066419B2 (en)
EP (1) EP3562827A1 (en)
JP (1) JP7109446B2 (en)
KR (1) KR20190104359A (en)
CN (1) CN110392686A (en)
AU (1) AU2017386417B2 (en)
BR (1) BR112019013388A2 (en)
CA (1) CA3048220A1 (en)
IL (1) IL267601A (en)
MX (1) MX2019007890A (en)
SG (1) SG10201910821XA (en)
WO (1) WO2018125746A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
KR20190104359A (en) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 1H-pyrrole-2,5-dione compound and method of using the same for inducing self-renewal of stem / progenitor supporting cells
JP2021533788A (en) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Compositions and Methods for Generating Hair Cells by Up-Controlling JAG-1
EP3837350A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating pi3k
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
CA3114113A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions and methods related to otic therapeutic agents
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CA3129273A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by inhibiting epigenetic targets
US20220160664A1 (en) 2019-02-08 2022-05-26 Frequency Therapeutics, Inc. Taz activators and wnt agonists for treating ear disorders
CN114340611A (en) 2019-04-08 2022-04-12 频率医疗公司 Combination of CHIR99021 and valproic acid for the treatment of hearing loss
CN111205231B (en) * 2020-02-24 2021-12-17 浙江大学 Lead compound as ANKRD22 inhibitor and application thereof
EP4337321A2 (en) * 2021-05-12 2024-03-20 University of Pittsburgh - of the Commonwealth System of Higher Education Engineered antimicrobial peptides and usage thereof

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5561163A (en) 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5837681A (en) 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
US6806358B1 (en) 1997-12-16 2004-10-19 University Of California San Diego Peptide inhibitor of TGF-β growth factors
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
EP1060160A2 (en) 1998-02-27 2000-12-20 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2146552B1 (en) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra INHIBITING PEPTIDES OF TGF / 31
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
WO2000059939A1 (en) 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
AU2072201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
JP2001275095A (en) 2000-03-27 2001-10-05 Sony Corp Communication method, communication service device, communication terminal device, and communication system
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
ATE305786T1 (en) 2000-03-30 2005-10-15 Curis Inc SMALL ORGANIC MOLECULES AS REGULATORS OF CELL PROLIFERATION
US6683108B1 (en) 2000-03-30 2004-01-27 Curis, Inc. Agonists of hedgehog signaling pathways and uses related thereto
US20050070578A1 (en) 2000-03-30 2005-03-31 Baxter Anthony David Small organic molecule regulators of cell proliferation
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
AU5301201A (en) 2000-03-31 2001-10-15 Gen Hospital Corp Methods of modulating hair growth
DE60129222T2 (en) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas HETEROCYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE GSK-3
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
WO2002044183A2 (en) 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
ATE326464T1 (en) 2000-12-08 2006-06-15 Ortho Mcneil Pharm Inc INDAZOLYL-SUBSTITUTED PYRROLIDINE COMPOUNDS AS KINASE INHIBITORS
US20050287128A1 (en) 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050227936A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
CN1951939A (en) 2001-05-24 2007-04-25 伊莱利利公司 Novel pyrrole derivatives as pharmaceutical agents
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
CA2463822A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
ES2276048T3 (en) * 2002-03-05 2007-06-16 Eli Lilly And Company PURINE DERIVATIVES AS CINASE INHIBITORS.
SE0200979D0 (en) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US20040006030A1 (en) 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
AU2003224335A1 (en) 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
JP2005539000A (en) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション 2-Phenylpyridin-4-yl derivatives as ALK5 inhibitors
EP1739087A1 (en) 2002-08-02 2007-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
DE60315677T2 (en) 2002-09-17 2008-06-05 Eli Lilly And Co., Indianapolis PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA TEMPERATURES FOR THE TREATMENT OF CANCER
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
MXPA05002982A (en) 2002-09-18 2005-06-22 Pfizer Prod Inc Triazole derivatives as transforming growth factor (tgf) inhibitors.
WO2004035132A2 (en) 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
WO2004058720A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 1,3,5-substitute indazole derivatives as compounds for targetting compounds capable of binding to the g-protein coupled receptor
EP1590347A1 (en) 2003-01-27 2005-11-02 Pfizer Products Inc. Isothiazole derivatives
US7189733B2 (en) 2003-03-12 2007-03-13 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
JP2006521398A (en) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド Bicyclic pyrimidine inhibitors of TGFβ
EP1633718B1 (en) 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
GB0316756D0 (en) 2003-07-17 2003-08-20 Bp Chem Int Ltd Process
US20060229266A1 (en) 2003-08-13 2006-10-12 Kumar Nalin M Silencing of tgf-beta receptor type II expression by sirna
US7387614B2 (en) 2003-08-26 2008-06-17 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
WO2005039570A1 (en) 2003-10-28 2005-05-06 Riken TGF-β INFORMATION TRANSFER PATHWAY INHIBITOR
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
GB0327908D0 (en) 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
MXPA06008157A (en) 2003-12-24 2007-09-07 Johnson & Johnson Treatment of malignant gliomas with tgf-beta inhibitors.
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
AR048335A1 (en) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
CA2568028A1 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
JP2007176795A (en) 2004-08-18 2007-07-12 Univ Nihon TGF-beta GENE EXPRESSION INHIBITOR
WO2006034207A2 (en) 2004-09-17 2006-03-30 Vanderbilt University Use of gsk3 inhibitors in combination with radiation therapies
ES2711213T3 (en) 2005-02-08 2019-04-30 Genzyme Corp TGFbeta antibodies
ZA200706530B (en) * 2005-02-09 2009-01-28 Arqule Inc Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
US20070066632A1 (en) 2005-03-25 2007-03-22 Scios, Inc. Fused bicyclic inhibitors of TGFbeta
WO2006105109A2 (en) 2005-03-29 2006-10-05 The Trustees Of The University Of Pennsylvania Methods for generating new hair follicles, treating baldness, and hair removal
CN103356704B (en) 2005-03-31 2015-09-30 斯丹姆涅恩有限公司 Prepare the method for the medicine in order to treat the ulcer caused by diabetic neuropathy
CN101341138B (en) 2005-06-30 2012-11-14 詹森药业有限公司 Cyclic anilino-pyridinotriazines as GSK-3 inhibitors
BRPI0613639A2 (en) 2005-07-22 2012-02-22 Lilly Co Eli compound, pharmaceutical composition, use of the compound, and process for producing a compound
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
JP5112322B2 (en) 2005-10-24 2013-01-09 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Use of a TGF-β1 inhibitor peptide in the manufacture of an immune response modulator
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
ITMI20060181A1 (en) 2006-02-03 2007-08-04 Univ Padova TGF-B MODULATORS AND THEIR USE
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
ES2419232T3 (en) 2006-06-27 2013-08-20 Shiseido Company, Limited Aggregate of cells comprising various kinds of soma-derived cells capable of forming a structure of the primitive organ type
TWM303325U (en) 2006-07-13 2006-12-21 Everlight Electronics Co Ltd Light emitting diode package
AU2007287319A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Pyrimidone compounds as GSK-3 inhibitors
JP5138253B2 (en) 2006-09-05 2013-02-06 東京エレクトロン株式会社 Annealing equipment
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080182859A1 (en) 2006-11-02 2008-07-31 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2008057469A1 (en) 2006-11-02 2008-05-15 Wyeth Small organic molecule regulators of cell proliferation
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
ES2446269T3 (en) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranyl-4-indolyl-maleimides as potent inhibitors of GSK-3 for neurodegenerative disorders
EP2146724A2 (en) 2007-03-16 2010-01-27 The Regent of the University of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
DE102007021348A1 (en) 2007-05-06 2008-11-20 Universitätsklinikum Hamburg-Eppendorf (UKE) A method for simulating the feel of an interaction of a guided object with a virtual three-dimensional object
CN101801961B (en) 2007-06-22 2014-09-24 艾科尔公司 Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
TWI428132B (en) 2007-07-02 2014-03-01 Lilly Co Eli Potentiation of cancer chemotherapy
DE102007032977A1 (en) 2007-07-16 2009-01-22 Universität Tübingen New cyclic amides, process for their preparation and their use
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
JP2010538003A (en) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー Thiazole and oxazole kinase inhibitors
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
SG10201607710UA (en) 2008-03-17 2016-11-29 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
RU2499592C2 (en) 2008-04-21 2013-11-27 Отономи, Инк. Pharmaceutical composition for treating ear diseases
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8822410B2 (en) 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120059021A1 (en) 2008-11-11 2012-03-08 University Of Washington Compositions and methods for treating cancer and methods for predicting a response to such treatments
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US9045737B2 (en) 2008-12-13 2015-06-02 Dnamicroarray, Inc. Artificial three-dimensional microenvironment niche culture
US20130039998A1 (en) 2008-12-24 2013-02-14 University Of Washington Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
WO2010104205A1 (en) 2009-03-11 2010-09-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
CA2765706A1 (en) 2009-06-17 2010-12-23 Aderans Research Institute, Inc. Methods and compositions for increasing trichogenic potency of dermal cells
WO2011019957A1 (en) 2009-08-12 2011-02-17 University Of Southern California Method for formation of induced pluripotent stem cells
FR2955324A1 (en) 2010-01-15 2011-07-22 Sanofi Aventis DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES
AU2010312240B2 (en) 2009-10-31 2016-12-15 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
US20110135756A1 (en) 2009-12-08 2011-06-09 University Of Washington Compositions and methods for protecting sensory hair cells
CN102844029A (en) 2009-12-28 2012-12-26 奥迪欧医药设备有限公司 Beta-carbolines for use in the treatment of hearing loss and vertigo
KR20120120307A (en) 2010-01-19 2012-11-01 아스트라제네카 아베 Pyrazine derivatives
WO2011109711A1 (en) 2010-03-05 2011-09-09 Duke University Glucocorticoid drugs as smoothened agonists
EP2550355B1 (en) 2010-03-22 2016-11-16 Takara Bio Europe AB Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of wnt-signalling pathway
EP2569430B1 (en) 2010-05-12 2018-10-17 The Trustees of Columbia University in the City of New York Methods for producing enteroendocrine cells that make and secrete insulin
ES2652363T3 (en) 2010-08-18 2018-02-01 Samumed, Llc Dicetonas and hydroxyketones as activators of the catenin signaling pathway
WO2012024581A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024584A2 (en) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
CN103459591B (en) 2010-11-02 2016-05-04 国立大学法人熊本大学 The manufacture method of enterocyte
FR2967498B1 (en) 2010-11-16 2015-01-02 Centre Nat Rech Scient USE OF QUINOLINONE DERIVATIVES AS A RESEARCH TOOL
EP2667881A4 (en) 2011-01-24 2015-04-22 Univ Leland Stanford Junior Methods for generating inner ear cells in vitro
WO2012115575A1 (en) 2011-02-21 2012-08-30 Biomatcell Ab Derivatives for inducing osteogenic differentiation
CN102276615B (en) * 2011-08-26 2013-10-23 四川大学 Method for preparing (-)-5-N-formalardeemin
CN103929963A (en) 2011-09-14 2014-07-16 萨穆梅德有限公司 Indazole-3-carboxamides and their use as WNT/beta-CATENIN signaling pathway inhibitors
EP2765188B1 (en) 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
WO2013126805A2 (en) 2012-02-24 2013-08-29 Fate Therapeutics, Inc. Small molecule compounds to treat hearing loss
HUE035089T2 (en) 2012-02-24 2018-05-02 Asd Therapeutics Partners Llc Thiadiazolidinediones as gsk-3 inhibitors
US9457009B2 (en) 2012-05-31 2016-10-04 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for preventing and treating auditory dysfunctions
EP2861603B1 (en) * 2012-06-18 2018-12-19 Dart NeuroScience (Cayman) Ltd 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders
TW201406758A (en) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd Tricyclic compounds
GB201212960D0 (en) 2012-07-20 2012-09-05 Common Services Agency Erythroid production
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
TW201417817A (en) 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Combination of GSK3 inhibitor and anti-DR5 antibody
ES2719776T3 (en) 2012-10-12 2019-07-16 Broad Inst Inc GSK3 inhibitors and methods of use thereof
CN105143445B (en) 2012-11-29 2020-07-07 宝生物欧洲公司 Maturation of hepatocyte-like cells derived from human pluripotent stem cells
AU2013352256A1 (en) 2012-11-29 2015-06-18 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
US20140248696A1 (en) 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
JP2016510745A (en) 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． BMP inhibitor and method of using the same
NZ713219A (en) 2013-03-14 2017-04-28 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
JP2016517888A (en) 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Oxysterol bone targeting drug for osteoselective bone formation
EP3013341A4 (en) * 2013-06-26 2017-02-08 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
WO2015175783A1 (en) 2014-05-15 2015-11-19 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
EP3206686B1 (en) 2014-08-20 2019-10-09 Samumed, LLC Gamma-diketones for treatment and prevention of aging skin and wrinkles
CN107073042A (en) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 Composition, the system and method for hearing loss are treated for producing inner ear hair cells
US20170305883A1 (en) 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US9913848B2 (en) 2016-03-02 2018-03-13 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using 1,2,3,4-tetrahydro-[1,4]diazepino[6,7, 1-hi]indolyl based compounds
US10016507B2 (en) 2016-03-02 2018-07-10 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III
KR20190104359A (en) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 1H-pyrrole-2,5-dione compound and method of using the same for inducing self-renewal of stem / progenitor supporting cells
US10383881B2 (en) 2016-12-30 2019-08-20 Frequency Therapeutics, Inc. 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same
EP3609998A1 (en) 2017-04-11 2020-02-19 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
WO2019126686A1 (en) 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
US20200316089A1 (en) 2017-12-21 2020-10-08 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same

Also Published As

Publication number Publication date
EP3562827A1 (en) 2019-11-06
IL267601A (en) 2019-08-29
AU2017386417A1 (en) 2019-07-11
CA3048220A1 (en) 2018-07-05
US11066419B2 (en) 2021-07-20
US20190352313A1 (en) 2019-11-21
CN110392686A (en) 2019-10-29
MX2019007890A (en) 2020-01-20
AU2017386417B2 (en) 2022-07-14
US20210300948A1 (en) 2021-09-30
JP7109446B2 (en) 2022-07-29
KR20190104359A (en) 2019-09-09
WO2018125746A1 (en) 2018-07-05
JP2020503340A (en) 2020-01-30
BR112019013388A2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
IL267601A (en) 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
IL261441B (en) Methods of generating mesenchymal stem cells which secrete neurotrophic factors
IL255547B (en) Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
IL272541A (en) Purified mesenchymal stem cell exosomes and uses thereof
IL241930B (en) Isolated naive pluripotent stem cells and methods of generating same
PL3145517T3 (en) Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
HUE058347T2 (en) Use of epimerase enzymes for conversion of fructose to allulose
IL240871B (en) Composition and methods for obtaining enriched mesenchymal stem cell cultures
ZA201704868B (en) Suspension culturing of pluripotent stem cells
PL3411473T3 (en) Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
GB201709599D0 (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
IL263265A (en) Use of mesenchymal stem cells and parts thereof
EP3013944A4 (en) Composition of mesenchymal stem cells
EP3383182C0 (en) Methods for generating functional hematopoietic stem cells
IL249170A0 (en) Method for preparing induced pluripotency stem cells from mesenchymal stem cells by using phlorotannin fraction
ZA201708773B (en) Agent for promoting migration of pluripotent stem cells
EP3452500A4 (en) Mesenchymal stem cell proliferation
SG11201703600YA (en) Method of distinguishing mesenchymal stem cells
KR101985095B9 (en) Methods for improving proliferation of stem cell using ethionamide
EP2954044A4 (en) Methods of combining mesenchymal stem cells and cartilage containing allografts, and products of combined mesenchymal stem cells and cartilage containing allografts
IL250293A0 (en) Method for preparing induced pluripotent stem cell line from mesenchymal stem cells, and cell line obtained thereby
HK1216107A1 (en) Methods of upscaling mesenchymal stromal cell production, compositions and kit thereof
EP3439610A4 (en) Therapeutic use of electroacupuncture-induced mesenchymal stem cells
ZA201500660B (en) Methods of upscaling mesenchymal stromal cell production, compositions and kit thereof
SG10201800796XA (en) Method of distinguishing mesenchymal stem cells